Neuphoria Therapeutics (NEUP) Income towards Parent Company (2023 - 2026)

Neuphoria Therapeutics (NEUP) has reported Income towards Parent Company for 4 consecutive years, with -$505063.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Income towards Parent Company fell 104.48% year-over-year to -$505063.0; the TTM figure through Mar 2026 stood at -$10.8 million (down 274.0% YoY), while the FY2025 annual figure was $6.3 million, up 141.49% from the prior year.
• Income towards Parent Company declined to -$505063.0 in Q1 2026 per NEUP's latest filing, from $1.9 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $11.3 million in Q1 2025 and bottomed at -$9.9 million in Q3 2025.
• Historically, Income towards Parent Company has averaged -$1.6 million across 4 years, with a median of -$2.2 million in 2025.
• On a YoY basis, Income towards Parent Company climbed as much as 505.38% in 2025 and fell as far as 1130.95% in 2025.
• Neuphoria Therapeutics' Income towards Parent Company stood at -$4.6 million in 2023, then soared by 57.33% to -$1.9 million in 2024, then jumped by 195.92% to $1.9 million in 2025, then tumbled by 127.09% to -$505063.0 in 2026.
• Business Quant data shows NEUP's Income towards Parent Company at -$505063.0 in Q1 2026, $1.9 million in Q4 2025, and -$9.9 million in Q3 2025.